Silence Therapeutics(SLN) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

SLN Silence Therapeutics

Watchlist

4.850
+0.110+2.32%

Close Mar 7 16:00 ET

4.840
-0.010-0.21%

Post 16:07 ET

229.04MMarket Cap-3.80P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up Slightly for Week
MT Newswires11:14 ET
Silence Therapeutics: Strategic Focus and Strong Financials Poised for Growth With Promising RNAi Pipeline
TipRanksMar 7 06:28 ET
Revenue Downgrade: Here's What Analysts Forecast For Silence Therapeutics Plc (NASDAQ:SLN)
Yahoo FinanceMar 6 05:41 ET
Express News | Morgan Stanley Maintains Overweight on Silence Therapeutics, Lowers Price Target to $45
BenzingaMar 5 09:08 ET
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
BusinesswireMar 5 08:00 ET
BMO Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating, Cuts Target Price to $25
Moomoo NewsMar 4 13:32 ET · Ratings

Comments

Trytosaveabit

Feb 27 07:31

Not too shabby

$Silence Therapeutics (SLN.US)$ Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.33) per share. This is a 32.65 percent increase over losses of $(0.49) per share from the same period last year. The company reported $43.26 million in sales this quarter. This is a 36.71 percent increase over sales of $31.64 million the same period last year.

PYUN970IHaveChosen

Jan 2 09:17

👀👀👀

$Silence Therapeutics (SLN.US)$

PYUN970IHaveChosen

Dec 20, 2024 13:40

👀👀👀……..

$Silence Therapeutics (SLN.US)$

Jaguar8

Dec 9, 2024 06:56

NEWS

$Silence Therapeutics (SLN.US)$
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting
Silence Therapeutics presented additional Phase 1 results for divesiran in polycythemia vera (PV) patients at the ASH Annual Meeting. The SANRECO study data showed substantial reduction in phlebotomy frequency and lower hematocrit levels in 19 PV patients. Following treatment, only five phlebotomies were required during t...

Mcsnacks H Tupack

Nov 22, 2024 02:52

Top 2 Long Term stocks(3 months)

$Silence Therapeutics (SLN.US)$ Stock rated a buy and with the lowest PT being $31. Had the same dip last year so it will be around February 21 when it reaches its PT.
$Rezolve AI (RZLV.US)$ Alot of short shares sold this month and in September. Reversal should be starting now that it has reached $1.63. First climb will be to 4.70 with that PT being at the end of December. February's PT will be 12.00. Partnerships with Microsoft and Google will push it until they re...

SLN Silence Therapeutics

Trade Overview

Capital Trend

News

Comments

Trending Stocks